| Sorafenib in advanced hepatocellular carcinoma JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, ... New England journal of medicine 359 (4), 378-390, 2008 | 14918 | 2008 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4012 | 2018 |
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... The Lancet 372 (9637), 449-456, 2008 | 3711 | 2008 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, C Porta, M Schmidinger, N Rioux-Leclercq, A Bex, V Khoo, ... Annals of Oncology 30 (5), 706-720, 2019 | 1576 | 2019 |
| Targeting PI3K/Akt/mTOR signaling in cancer C Porta, C Paglino, A Mosca Frontiers in oncology 4, 64, 2014 | 1544 | 2014 |
| Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors RJ Motzer, B Escudier, S Oudard, TE Hutson, C Porta, S Bracarda, ... Cancer 116 (18), 4256-4265, 2010 | 1513 | 2010 |
| Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ... New England Journal of Medicine 384 (14), 1289-1300, 2021 | 1224 | 2021 |
| Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ... New England Journal of Medicine 384 (9), 829-841, 2021 | 1216 | 2021 |
| Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ... Journal of hepatology 57 (4), 821-829, 2012 | 930 | 2012 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 895 | 2019 |
| Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial ME Gore, C Szczylik, C Porta, S Bracarda, GA Bjarnason, S Oudard, ... The lancet oncology 10 (8), 757-763, 2009 | 709 | 2009 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 708 | 2019 |
| Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study A Santoro, L Rimassa, I Borbath, B Daniele, S Salvagni, JL Van Laethem, ... The lancet oncology 14 (1), 55-63, 2013 | 657 | 2013 |
| Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. B Escudier, C Porta, P Bono, T Powles, T Eisen, CN Sternberg, ... | 478 | 2014 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, C Porta, M Schmidinger, F Algaba, JJ Patard, V Khoo, T Eisen, ... Annals of oncology 25, iii49-iii56, 2014 | 456 | 2014 |
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises F Massari, M Santoni, C Ciccarese, D Santini, S Alfieri, G Martignoni, ... Cancer treatment reviews 41 (2), 114-121, 2015 | 455 | 2015 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, ... ESMO open 5 (6), e001079, 2020 | 454 | 2020 |
| Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Escudier, T Eisen, C Porta, JJ Patard, V Khoo, F Algaba, P Mulders, ... Annals of oncology 23, vii65-vii71, 2012 | 390 | 2012 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 387 | 2020 |
| Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study L Rimassa, E Assenat, M Peck-Radosavljevic, M Pracht, V Zagonel, ... The Lancet Oncology 19 (5), 682-693, 2018 | 343 | 2018 |
